Glory Tablet (Clopidogrel Hydrogen Sulfate)

Adult dose

○ Adults 1. For patients with ischemic stroke, myocardial infarction, or peripheral arterial disease, administer clopidogrel 75 mg orally once daily. 2. For patients with acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), on the day treatment with this medicine is initiated, begin with a loading dose of 300 mg once daily, followed by an oral maintenance dose of 75 mg once daily. Aspirin 75 ~ 325 mg should be administered concomitantly with this medicine once daily. 3. For patients with atrial fibrillation, administer this medicine 75 mg orally once daily. Aspirin 75 ~ 100 mg should be administered concomitantly with this medicine once daily. ○ Patients with renal impairment: Experience with treatment in patients with renal impairment is limited. ○ Patients with hepatic impairment: Experience with treatment in patients with moderate liver disease and a bleeding diathesis is limited. This medicine may be administered with or without food.

This medication helps prevent platelets from clumping together and facilitates smooth blood flow. Its effects may be reduced in individuals who have a genetic deficiency in the enzymes required to activate this medication. In such cases, the risk of heart attacks or cerebrovascular accidents may increase, and alternative treatments should be considered in consultation with a physician. Additionally, concomitant use of certain medications that activate these enzymes may increase the concentration of the active ingredient of this medication, raising the risk of bleeding; therefore, co-prescribing should be avoided. Patients with known allergies to this medication, those experiencing bleeding, individuals with severe liver damage, nursing mothers, and those with lactose intolerance should not take this medication. Patients with a high risk of bleeding, impaired liver or kidney function, those who have recently experienced a stroke, those with severe hypertension, elderly patients, and those with low body weight should use this medication cautiously. Notably, patients scheduled for surgery should discontinue this medication 5 to 7 days prior to the procedure and report any signs of bleeding to their physician immediately. This medication may increase the risk of bleeding when taken with aspirin, anticoagulants, non-steroidal anti-inflammatory drugs (NSAIDs), certain antidepressants, and other medications that carry a risk of bleeding. During treatment, bleeding may take longer to stop, so if there is any bleeding or it persists, medical personnel should be notified immediately. Rarely, this medication can cause a decrease in certain blood cell counts, so tests may be necessary if symptoms of infection or unusual symptoms occur. During pregnancy, risks to the fetus have not been confirmed; however, due to the risk of bleeding, it should be used only when necessary. Nursing mothers should consult a physician regarding whether to discontinue breastfeeding as this medication can pass into breast milk. In cases of overdose, the risk of bleeding may increase, but there is currently no antidote for this medication; platelet transfusion can reverse its effects if necessary. To ensure safety for children, this medication should be stored out of reach of children and should not be transferred to another container. This medication should also be administered with caution to elderly patients or those with compromised kidney function, and any new medications started during treatment or surgical plans should be communicated to healthcare providers.

• Hemorrhage
• gastrointestinal bleeding
• purpura
• contusion
• hematoma
• epistaxis
• hematoma
• hematuria
• intraocular hemorrhage
• intracranial hemorrhage

This medication should be stored in a tightly sealed container to protect it from air or moisture exposure. The recommended storage temperature is between 1°C and 30°C at room temperature.

Appearance

Pink round film-coated tablet

Package unit

30 tablets/bottle, 100 tablets/bottle